NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
Clinical Trials
36 trialsNCT03641326 2022-04-19
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00853125 2021-04-27
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00859456 2019-11-04
Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
Columbia University
Phase 2 Terminated
NCT00408252 2019-09-19
Efficacy of SU 011248 in Head And Neck Carcinoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT01391130 2019-07-23
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Terminated
NCT01118351 2019-05-01
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00953459 2018-07-26
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02626754 2018-06-26
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Taipei Veterans General Hospital, Taiwan
Phase 2 Terminated
NCT00824538 2018-04-05
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
University of California, San Francisco
Phase 2 Terminated
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01042795 2017-06-28
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Phase 2 Terminated
NCT00524316 2017-05-09
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02071641 2017-04-07
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
Amsterdam UMC, location VUmc
Phase 2 Terminated
NCT00482911 2017-03-27
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00912912 2016-04-15
Sunitinib Malate in Refractory Germ Cell Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00859339 2016-04-14
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00734851 2015-12-23
Multimodality Phase II Study in Prostate Cancer
Duke University
Phase 2 Terminated
NCT00480935 2015-12-09
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
University Health Network, Toronto
Phase 2 Terminated
NCT00982657 2015-11-20
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT00923117 2015-09-30
Sunitinib to Treat Recurrent Brain Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT00393796 2014-11-13
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00387426 2014-05-28
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01215565 2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01216657 2013-06-04
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
Krankenhaus Nordwest
Phase 2 Terminated
NCT00609622 2012-10-11
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00434356 2009-12-03
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Genentech, Inc.
Phase 2 Terminated
NCT00434226 2009-08-21
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Genentech, Inc.
Phase 2 Terminated